Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Core Viewpoint - Acurx Pharmaceuticals has announced a 1-for-20 reverse stock split to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement, effective August 4, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every twenty shares of common stock into one share, with no fractional shares issued; stockholders will receive cash for any fractional shares [2]. - The number of outstanding shares will decrease from approximately 30,764,540 to about 1,538,227, while the total authorized shares will remain unchanged [3]. - Stockholders holding shares electronically will not need to take action, while those with physical certificates will receive instructions for exchanging them [4]. Group 2: Company Overview - Acurx Pharmaceuticals is focused on developing a new class of antibiotics targeting difficult-to-treat bacterial infections, specifically Gram-positive bacteria [5]. - The lead product candidate, ibezapolstat, is ready for Phase 3 trials, with plans for international clinical trials next year, pending financing [5]. - The preclinical pipeline includes an oral product candidate for treating Acute Bacterial Skin and Skin Structure Infections and a development program for inhaled anthrax [5].